Wall Street Analysts Predict a 45% Upside in Syndax (SNDX): Here's What You Should KnowZacks Investment Research • 12/19/22
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 12/14/22
Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual MeetingPRNewsWire • 12/10/22
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)PRNewsWire • 12/08/22
Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute LeukemiaPRNewsWire • 12/05/22
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical OncologyPRNewsWire • 12/05/22
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial OfficerPRNewsWire • 12/02/22
Can Syndax (SNDX) Climb 39% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 12/01/22
Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business UpdatePRNewsWire • 11/03/22
Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute LeukemiasPRNewsWire • 11/03/22
Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022PRNewsWire • 10/27/22
Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/08/22
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A StandstillInvestors Business Daily • 08/08/22
Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business UpdatePRNewsWire • 08/08/22
Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022PRNewsWire • 08/02/22
Does Syndax (SNDX) Have the Potential to Rally 67% as Wall Street Analysts Expect?Zacks Investment Research • 08/01/22
Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial OfficerPRNewsWire • 06/13/22